Testimonials

Genentech BioOncology
Why has Genentech BioOncology chosen to make a major gift to the ONS Foundation’s  Silver Anniversary Campaign? 
Genentech BioOncology was the first biotech company founded in 1976 by biochemist Herb Boyer and venture capitalist Bob Swanson. Ever since we have aspired to develop innovative therapeutics that transform the way cancer is treated and improve patients’ lives. At Genentech BioOncology, we believe that investing in the education, research and development of oncology nurses is important to changing the way cancer is treated. Our commitment to the oncology nursing community will help to ensure high standards of integrity in contributing to the best interest of patients.
 
Why has Genentech BioOncology consistently valued its interaction with oncology nursing?
At Genentech BioOncology, we believe that investing in the education, research and development of oncology nurses is important to changing the way cancer is treated.  Our commitment to the oncology nursing community will help to ensure high standards of integrity in contributing to the best interest of patients.

What do you feel is Genentech BioOncology’s most valuable contribution to cancer care?
At Genentech BioOncology, science remains the focus of our organization. Our ultimate goal is to fundamentally change the way cancer is treated and help move cancer toward a more chronic and manageable disease. Our FDA-approved products – Rituxan, Herceptin, Avastin and Tarceva - already provide new therapeutic options to hundreds of thousands of cancer patients and we are working to build upon this foundation.  As the industry leader in research and development, we are constantly looking for new breakthrough therapies to address unmet medical needs.  We invest in clinical trial programs to answer real science questions and yield definitive results.

Amgen Inc.
Why has Amgen chosen to make such a significant gift in support of the ONS Foundation’s Silver Anniversary campaign?
Amgen recognizes that oncology nurses are key members of the cancer healthcare team. Our $1.5 million contribution will help lead the initial phase of the Foundation’s launch of an important endowment campaign that will focus on three important issues that will help advance the specialty of oncology nursing. The grant will provide funding for nursing research, education and leadership programs. We believe these programs will make a difference for both the oncology nurses on the frontlines of cancer care as well as help improve patient care.

Why has Amgen consistently valued its interaction with oncology nurses?
Amgen is committed to fighting cancer in all the ways we can. We understand that the best medical care is important when battling cancer, and we value the pivotal role oncology nurses play in helping educate and guide patients through treatment. At Amgen, we are committed to helping oncology nurses deliver high quality, comprehensive cancer care for their patients.  In fact, we have developed resources for oncology nurses, including professional support and educational materials. As part of our mission to serve patients, we look forward to continued partnerships with oncology nurses.

How has Amgen contributed to improved cancer care?
Amgen products have transformed the treatment of anemia and neutropenia in people undergoing chemotherapy.  While continuing to develop supportive care therapies, we are also developing innovative targeted therapies to attack cancer itself.  Focusing on seven major areas of cancer research, the company has many targeted therapies in the pipeline directed against cancer and serious unmet needs related to cancer, such as muscle wasting disorders and bone loss induced by hormone ablation therapy.  Behind those, we have more potential oncology therapeutics in earlier stages of development.

Cynthia Schwalm
Vice President and General Manager, Amgen Oncology

GlaxoSmithKline
Why has GlaxoSmithKline chosen to support the ONS Foundation’s Silver Anniversary Campaign?
GlaxoSmithKline and the ONS Foundation have a shared commitment and common cause to help patients now and in the future.  The ONS Foundation’s plan for opportunities in education, research, and leadership that will serve oncology nurses and the patients for whom they care is an inspiration and example to us all.  As a strong supporter of oncology nurses and patients with cancer, GlaxoSmithKline wanted to take a lead role in this campaign.

Why has GlaxoSmithKline consistently valued its interaction with oncology nursing?
GlaxoSmithKline values its interaction with oncology nursing because it extends to all settings where assisting patients is involved, such as prevention, diagnosis, and treatment, counseling and survivorship.  Oncology nurses work with patients, families, communities, and other healthcare professionals to ensure the best healthcare goals.  Their commitment and dedication is unsurpassed.

What do you feel is GlaxoSmithKline’s most valuable contribution to cancer care?
GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of life by enabling people to do more, feel better, and live longer.  GlaxoSmithKline’s broad portfolio of innovative medicines – past, present and future – bring treatment, relief, prevention and hope to patients with cancer.  Products including prescription drugs indicated for a variety of tumor types, consumer products for smoking cessation, alcohol free mouthwash, supportive care products, and a rich pipeline with many potential new products, including cancer vaccines, are the most valuable contribution GlaxoSmithKline makes to help benefit patients and aid in the fight against cancer.

David Moules
Vice President, Oncology Business Unit, GlaxoSmithKline

sanofi-aventis
Why has sanofi-aventis chosen to support the ONS Foundation Silver Anniversary Campaign?
Sanofi-aventis’ work in oncology is based on one overarching dynamic: “Because Health Matters.” The Silver Anniversary Campaign exemplifies that credo, providing nurses with the training and opportunity to contribute their experience to helping patients live longer with the highest quality-of-life.  Supporting ONS initiatives is one way sanofi-aventis helps to make a difference in improving cancer care, one core ONS value shared by the company.  Both ONS and sanofi-aventis bring integrity and leadership in the fight against cancer and we share a strong commitment to upholding excellence and innovation. We are proud of our association with ONS “Because Health Matters.”

Why has sanofi-aventis consistently valued its interaction with oncology nursing?
Sanofi-aventis believes strongly in the need for a multidisciplinary team in cancer care that includes oncology nurses. Close collaboration among all members of the treatment team including medical oncologists, radiologists and surgeons as well as oncology nurses, patients and caregivers is the best approach to developing an integrated, effective treatment strategy.  Working closely with the patient from diagnosis through treatment, oncology nurses often provide “the best medicine” to patients through education. Sanofi-aventis regards the oncology nurse as a critical healthcare professional to learn from in our efforts to meet cancer patient needs for the development of effective and well-tolerated treatments.

What do you feel is sanofi-aventis' most valuable contribution to cancer care?
The spirit of courageous exploration is a driving force at sanofi-aventis. We have played a major role in developing chemotherapy drugs that remain the backbone of cancer therapy.  With our strong foundation in oncology research and development, sanofi-aventis has expertise in a range of cancer types and disease stages.  We remain committed to providing safe and effective therapeutics to help healthcare professionals provide cutting-edge patient care, and will continue to respond to ongoing challenges in the battle against cancer.  

Frank Clyburn
Vice President & Head of Oncology & Internal Medicine Business Units, sanofi-aventis